Abstract:Background: Identifying drug-binding targets and their corresponding sites is crucial for drug discovery and mechanism studies. Limited proteolysis-coupled mass spectrometry (LiP-MS) is a sophisticated method used for the detection of compound and protein interactions. However, in some cases, LiP-MS cannot identify the target proteins due to the small structure changes or the lack of enrichment of low-abundant protein. To overcome this drawback, we developed a thermostability-assisted limited proteolysis-coupled mass spectrometry (TALiP-MS) approach for efficient drug target discovery. Results: We proved that the novel strategy, TALiP-MS, could efficiently identify target proteins of various ligands, including cyclosporin A (a calcineurin inhibitor), geldanamycin (an HSP90 inhibitor), and staurosporine (a kinase inhibitor), with accurately recognizing drug-binding domains. The TALiP protocol increased the number of target peptides detected in LiP-MS experiments by 2- to 8-fold. Meanwhile, the TALiP-MS approach can not only identify both ligand-binding stability and destabilization proteins but also shows high complementarity with the thermal proteome profiling (TPP) and machine learning-based limited proteolysis (LiP-Quant) methods. The developed TALiP-MS approach was applied to identify the target proteins of celastrol (CEL), a natural product known for its strong antioxidant and anti-cancer angiogenesis effect. Among them, four proteins, MTHFD1, UBA1, ACLY, and SND1 were further validated for their strong affinity to CEL by using cellular thermal shift assay. Additionally, the destabilized proteins induced by CEL such as TAGLN2 and CFL1 were also validated. Significance: Collectively, these findings underscore the efficacy of the TALiP-MS method for identifying drug targets, elucidating binding sites, and even detecting drug-induced conformational changes in target proteins in complex proteomes.

Computational analysis of ligand dose range thermal proteome profiles

A computational method for detection of ligand-binding proteins from dose range thermal proteome profiles

Large-scale characterization of drug mechanism of action using proteome-wide thermal shift assays

Cell surface thermal proteome profiling tracks perturbations and drug targets on the plasma membrane

Thermodynamic analysis of protein-ligand binding interactions in complex biological mixtures using the stability of proteins from rates of oxidation

Tracking cancer drugs in living cells by thermal profiling of the proteome

Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells

Proteome thermal stability reflects organ physiology and identifies drug-target engagement in vivo

Thermostability-assisted limited proteolysis-coupled mass spectrometry for capturing drug target proteins and sites

Determining the In Vitro Ligand-Target Interaction by Cellular Thermal Shift Assay and Isothermal Dose-Response Fingerprint Assay

Determination of Protein-Ligand Binding Affinities by Thermal Shift Assay

Chemical Proteomics-based Target Prioritization through a Residue Agnostic Ligandability Assessment Platform

Computational Analysis of Heat Capacity Effects in Protein-Ligand Binding

Insights into the Molecular Mechanisms of Protein-Ligand Interactions by Molecular Docking and Molecular Dynamics Simulation: A Case of Oligopeptide Binding Protein

Precipitate-Supported Thermal Proteome Profiling Coupled with Deep Learning for Comprehensive Screening of Drug Target Proteins

Identifying drug targets in tissues and whole blood with thermal-shift profiling

Leveraging nonstructural data to predict structures and affinities of protein-ligand complexes

Identifying The Proteins To Which Small-Molecule Probes And Drugs Bind In Cells

Recent advances in computational and experimental protein-ligand affinity determination techniques

Large-Scale Ligand Perturbations of the Protein Conformational Landscape Reveal State-Specific Interaction Hotspots

Stability-based approaches in chemoproteomics